Evidence map›Paper›PMID 35677519›Full record

ArticleJournal of clinical and experimental hepatology

Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.

Yashwant Patidar, Karamvir Chandel, Naveen K Condati, Shyam V Srinivasan, Amar Mukund, Shiv K Sarin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yashwant PatidarDepartment of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Karamvir ChandelDepartment of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Naveen K CondatiDepartment of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Shyam V SrinivasanDepartment of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Amar MukundDepartment of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India.
Shiv K SarinDepartment of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Advanced-stage hepatocellular carcinoma is a heterogeneous group with limited treatment options. TACE has been advocated recently by various study groups. The purpose of this study was to evaluate if TACE in combination with sorafenib, as well as TACE alone, was safe and efficacious in treating BCLC stage C HCC. Methods: A retrospective evaluation of the clinical data of 78 patients with BCLC stage C HCC who received either TACE-sorafenib (TS) combination therapy or TACE monotherapy as their first treatment was done. The two groups were compared in terms of radiological tumor response 1 month after the intervention. The two groups were also compared in terms of time to progression (TTP), overall survival (OS), and adverse events. Results: The disease control rate (44.9% and 25.8%, respectively, Conclusion: TS combination therapy in advanced-stage (BCLC-C) HCC significantly improved disease control rate, TTP, and OS compared with TACE alone, without any significant increase in adverse reactions.

Indexed as

ALT, Alanine aminotransferaseAST, Aspartate aminotransferaseBCLC, Barcelona-Clinic Liver CancerCTCAE, Common terminology criteria for adverse eventsCT, Computed tomographyCTP, Child–Turcotte–PughECOG, Eastern Cooperative GroupEHS, Extrahepatic spreadHCC, Hepatocellular carcinomahepatocellular carcinoma (HCC)m-RECIST, Modified Response Evaluation Criteria in Solid TumorsMRI, Magnetic resonance imagingMVI, Macrovascular invasionOS, Overall survivaloverall survivalPS, Performance statussorafenibSPSS, Statistical Package for Social SciencesTACETACE, Transarterial chemoembolisationTS, TACE-sorafenibTTP, Time to tumor progression

Identifiers

PMID35677519
PMCPMC9168730

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.